Begin main content

Open Calls for Patient Input

This page lists Common Drug Review (CDR) drug applications received by CADTH and the deadlines for filing patient group input for each drug. For more information about how to provide input, please visit the CDR Patient Input page

TBC (glecaprevir pibrentasvir )

Indications: Hepatitis C, chronic

Call For Patient Input: May 11, 2017

Patient Input Closed: June 30, 2017

Galafold (migalastat)

Indications: Fabry Disease

Call For Patient Input: May 5, 2017

Patient Input Closed: June 26, 2017

Tresiba (insulin degludec)

Indications: Diabetes Mellitus, Type 2

Call For Patient Input: May 2, 2017

Patient Input Closed: June 21, 2017

Adlyxine (lixisenatide)

Indications: Diabetes mellitus, Type 2

Call For Patient Input: April 26, 2017

Patient Input Closed: June 15, 2017

TBC (ocrelizumab)

Indications: multiple sclerosis, relapsing

Call For Patient Input: April 18, 2017

Patient Input Closed: June 7, 2017

Ikervis (cyclosporine)

Indications: keratitis, severe

Call For Patient Input: April 17, 2017

Patient Input Closed: June 6, 2017